insight

Insight Enterprises Inc.

In receiving this accolade, Insight is recognized for its demonstrated leadership in leveraging innovative teammate engagement and recognition programs.

$NSIT Insight Enterprises shares are trading higher after the company reported better-than-expected Q4 adjusted EPS.

$NSIT Insight Recognized as One of World’s Top Female-Friendly Companies https://www.otcdynamics.com/nsit-insight-recognized-as-one-of-worlds-top-female-friendly-companies

Insight Acquisition Corp - Ordinary Shares - Class A

SELLAS Life Sciences Group Inc

buying

$SLS  I wont be buying anymore shares until the CEO can show is company is worth at least 150m marketcap 
 
Look at the 3 year chart be warned the CEO is a scam artist and a liar

You are better off hoarding cash vs buying into a company where the staff sells free shares and does not deserve pay raises during a economic crisis/recession.

$SLS  No one should be buying in at these prices though.

$SLS SERIOUSLY STOP FUCKING RUNNING ALL THE BUYING OTC DARK POOL!!!

This MM is refusing to honor order flow, they are refusing to move the price higher when buying comes in, they are dictating price direction and that&#39;s not their fucking job.

HOW THE FUCK DID THEY JUST FILL 24k BUYING VOLUME AND NOT A SINGLE $.01 MOVE!!!!

but buying inflow and a 5K buy order and yet POS MM will not let it fucking go!! !

application

Gfh009 is a joke and will ruin this stock until 3d meds sees fda approval for aml gps.

16/16 
In all 3 Options GPs gets FDA approval due to QOL, venclexta, onureg, oralAz - all Cr1 salvage agents are highly toxic.

This concerns me, we get the dreaded not statistically relevant ruling from the FDA.

- OUTRIGHT LIE saying THEN 52 weeks - PURE BS 
- OUTRIGHT LIE saying THEN patients need to Die 
Co is now on RECord Reiterating 80 Events, patient deaths in Q1Q2 
That is the fda green light moment.

announcement

You fucked up and shorted NCI non dilutive funding announcement and patients living longer news.

$SLS they supposedly hired a lawyer fill time and this was never announced .

The shorts feeling the pain on their announcement.

$SLS For those predicting some big announcement from Sellas on the 14th at the Regal symposium, you are going to be terribly disappointed.

investor

What a freaking smack in the face to investors.

Angelos has intentionally screwed the long term investor.

$SLS I find it arrogant that SLS would even investors were concerned about their SIVB exposure.

but after doing an offering and the way the market is, the company should be giving some communication,  otherwise you are showing you really don&#39;t care about long term  investors,  personally  I&#39;m not impressed with the way it&#39;s been handled.

$SLS This is a JOKE and the JOKE is on the real investors ☹️

$SLS SLS investors have two problems now.

If you’re an experienced investor and you buy this scam, you deserve to lose you your investment.

$SLS No one should buy  in to this unless you are new investor.

They need to communicate and support their investors and shareholders.

Scary that I bought 2 years ago 9000 shares $6.50 average price to see this today just seems like he doesn’t care at all for investors why would he?

patient

It reported positive outcomes in pleural mesothelioma patients, including:
Improved survival: Study patients lived around 11 months.

* Best Available Therapy offers 6-8 months of Overall Survival  
* All pooled Regal patients, BAT and Gps combined, is 16 months.

* Best Available Therapy offers 6-8 months of Overall Survival 
* All pooled Regal patients, BAT and Gps combined, is 16 months.

Now phase 3 trial is showing similar results to date where patients are living longer after Galinpepimut-S up to 1.5 year longer is a breakthrough for AML patients.

- Best available treatment 6-8 months of os.

- Cured GPS patients, continue to elongate the OS curve in Gps favor every day that goes by.

$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.

$SLS NCT update, nice…
They target 140 patients in 110 investigational sites.

news

$SLS With news on its way, the confidence built in the science, fear factor is gone.

$SLS No breaking news here regarding Sellas, and its well above my understanding,

$SLS good news, at the current rate and the ridiculous prices, in about a month you can buy this company for free.

My guess is that they generated ~3m revenue through the EAP, which would be really great news.

This is a rare opportunity that you know the news is grossly good(it convinced in investor(s)) and still have the chance to load and make 50 to 100% in .month or so.

plenty of upside if there is positive news.

$SLS they picked a great day for this news. lol

So much for this offering being good news.

Positive trial data/results supported with bullish news and sentiment! 4.

trial

PROC data are excellent compared to any combo trials.

But yesterdays paper also has me considering, if there isn&#39;t a deal with $mrk or $BMY or some other CPI BP  
--- That data is Best In Class - best in clinic, best in trial too.

The nation’s best means the O&#39;Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.

Gps is doing what it has done in every single trial and its the reason Patients are living 3 fold longer than patients on best available treatments.

Treatment with GFH009 resulted in 90 to 100 percent cancer inhibition at dose levels equivalent to those already demonstrated to be safe in patients in the ongoing Phase 1 trial with no viable cancer cells at the highest dose levels.

cancer

These patients experienced about 35% longer survival than has been reported for other second-line therapies.

Good cancer stock from what I hear in 2028.

$MRK Ovarian cancer data final P2 results are better than any other drugs by a mile.

They address a broad range of cancer indications.

$SLS Gps arm 22 months of median Overall Survival  
Best Available Therapy 8.

Top Stocks matching your search for "insight shorts"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

NSIT

Insight Enterprises Inc.

22.69%

$112.87 - $138.49

Mar, 20, 2023

Feb, 9, 2023

INAQ

Insight Acquisition Corp - Ordinary Shares - Class A

0.40%

$10.16 - $10.20

SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Jan, 18, 2023

NSIT

Insight Enterprises Inc.

22.69%

$112.87 - $138.49

INAQ

Insight Acquisition Corp - Ordinary Shares - Class A

0.40%

$10.16 - $10.20

SLS

SELLAS Life Sciences Group Inc

-63.99%

$3.61 - $1.30

Jan, 18, 2023